The RiMO technology addresses unmet medical needs of cancer patients by reducing X-ray doses to enhance the efficacy of radiotherapy. RiMO Therapeutics pursues strategic collaborations and licensing in tandem with internal development to maximize the potential of the RiMO technology.
Currently, RiMO Therapeutics focuses on RiMO formulations that can not only reduce X-ray doses in the novel radiotherapy-radiodynamic therapy (RT-RDT) mode of action but also enhance checkpoint blockade immunotherapy by increasing T cell infiltration into the tumors. RiMO Therapeutics welcomes partnership with pharmaceutical companies to potentiate current cancer immunotherapies and increase response rates.
For information on partnering with RiMO Therapeutics, please contact Dr. Wenbin Lin, Founder and Chairman, at lin@rimorx.com.